Our unique IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas.

FPT155 is a soluble CD80 fusion protein. It stimulates anti-tumor immunity and efficiently co-stimulates potent anti-tumor activity in vivo, inducing a favorable microenvironment for an anti-tumor immune response.  

FPT155 uses the binding interactions of soluble CD80 to:

  • Directly engage CD28 to enhance its co-stimulatory activity (without super agonism)
  • Block CTLA-4 from competing for endogenous CD80, allowing CD28 signaling to prevail in T cell activation

FPT155 is being studied for the treatment of solid tumors. We initiated a Phase 1 clinical trial of FPT155 in Australia in the fourth quarter of 2018.